TVABR101 Tn monoclonal antibody

產品介紹

Scientific study 
Tn antigen (N-acetyl galactosamine O-linked to serine or threonine, GalNAc-O-Ser/Thr) (Figure 1), a mucin-type O-linked glycan, is a well-established cell surface marker for tumor diagnosis. Its elevated levels have been correlated with cancer progression and prognosis (1-5).

Applying mouse anti-Tn monoclonal antibody for cancer tissue IHC assay, a significant increase in the levels of Tn antigen was observed in prostate cancer (6), oral squamous cell carcinoma, colon cancer (7), pancreas cancer and in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) of breast cancer, but not in normal prostate, colon, and breast tissue. Examination of cervical cancer tissues demonstrated high levels of Tn in moderately to poorly differentiated tumors and low levels of Tn in well-differentiated cervical cancer tissues (8).

Figure 1. The chemical structure of Tn

Anti-Tn monoclonal antibody (Catglog # TVABR101)

Tn monoclonal antibody 

貨號：TVABR101 

應用

產品資訊

實驗數據

西方墨點法 (Western blot)

Western blot analysis of Tn substrate (Lane 1) and carrier protein (Lane 2) using anti-Tn monoclonal antibody TVABR101 at 1/1,000 dilution.

Goat anti-mouse IgG, human ads-HRP (1030-05, SouthernBiotech) was used as secondary antibody at 1/5,000 dilution.

 免疫細胞化學 (Immunocytochemistry, ICC assay)

Figure 2.  The mouse anti-Tn monoclonal antibody (Catalog # TVABR101) shows positive results in the PC9 cancer cell line ICC assay.

免疫組織化學染色法 (immunohistochemistry, IHC)

Figure 3.  This image shows human colon tissue stained with TVABR101 at 1/50 dilution. Cytoplasmic staining was observed in many colon cancer cells.

These images show human breast, lung and colon tissue stained with TVABR101 at 1/150 dilution.

參考資料

1. Ju T, Otto, VI, Cummings RD. The Tn Antigen—Structural Simplicity and Biological Complexity. Angew. Chem. Int. Ed. 2011, 50, 1770-1791.
2. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nature reviews Drug discovery. 2005; 4:477-488.
3. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Kurosaki N, Ayabe H, Arisawa K. Preoperative serum levels of sialyl Lewis(a), sialyl Lewis(x), and sialyl Tn antigens as prognostic markers after curative resection for colorectal cancer. Cancer detection and prevention. 2001; 25:299-308.
4. Freire T, Bay S, von Mensdorff-Pouilly S, Osinaga E. Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression. Cancer research. 2005; 65:7880-7887.
5. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998; 4:295-302.
6. Chiang H.-L., Lin, C.-Y., Jan, F.-D., Lin, Y.-S., Chia-Tse Hsu, C.-T., Jacqueline Whang-Peng, J., Liu, L. F., Nieh, S., Chun-Cheng Lin, C.-C., Hwang, J. A novel synthetic bipartite carrier protein for developing glycotope-based vaccines. Vaccine 2012: 30, 7573-7581.
7. Lin C-Y, Ho J-Y, Hsieh M-T, Chiang H-L, Chuang J-M, Whang-Peng J, Chang Y-C, Tseng Y-H, Chen S-F, Nieh S, Hwang J. Reciprocal relationship of Tn/NF-jB and sTn as an indicator of the prognosis of oral squamous cell carcinoma. Histopathology 2014: 64, 713–721.
8. Ho CW, Lin CY, Liaw YW, et al. The cytokine-cosmc signaling axis upregulates the tumor-associated carbohydrate antigen Tn. Oncotarget. 2016 ; 7 (38): 61930 - 61944.